Note 9 - Revenue

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

9

. Revenue

We currently operate as

one

operating segment focusing on biopreservation tools.

The following table disaggregates revenue by market segment and distributors:

	Three Months Ended March 31,
(I n thousands)	2019		2018
Net product sales:
Regenerative medicine	$	2,179	$	2,104
Drug discovery		238		377
BioBanking		249		295
Distributors		3,104		1,039
Total revenues	$	5,770	$	3,815